TransCode Therapeutics, Inc. (RNAZ) NASDAQ
5.50
+0.21(+3.97%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.50
+0.21(+3.97%)
Currency In USD
| Previous Close | 5.29 |
| Open | 5.45 |
| Day High | 5.5 |
| Day Low | 5.34 |
| 52-Week High | 20.99 |
| 52-Week Low | 5.01 |
| Volume | 3,002 |
| Average Volume | 9,198 |
| Market Cap | 5.23M |
| PE | -1.48 |
| EPS | -3.71 |
| Moving Average 50 Days | 7.92 |
| Moving Average 200 Days | 9.52 |
| Change | 0.21 |
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
GlobeNewswire Inc.
Nov 29, 2024 9:25 PM GMT
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
GlobeNewswire Inc.
Nov 27, 2024 12:00 PM GMT
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a securities purchase ag
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
GlobeNewswire Inc.
Nov 25, 2024 12:00 PM GMT
Split designed to achieve compliance with Nasdaq minimum bid price requirementsBOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effecti